Efrat Luttwak

Sep 6, 2023 | targetedonc.com | Gilles Salles |Efrat Luttwak

Bispecific antibodies (BsAbs) represent a significant therapeutic advance in the management of follicular lymphoma (FL).1 The safety profile and high response rates of BsAbs suggest a promising and well-tolerated treatment option for patients with FL. The use of BsAbs has the potential to revolutionize the management of FL.

Jun 9, 2023 | pubmed.ncbi.nlm.nih.gov | Smith MR |Efrat Luttwak |Mitchell Smith |Zelenetz AD

Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software